Piridoxina en el manejo de disquinesias tardías: un estudio placebo controlado, randomizado, doble ciego y cruzado

Venegas F., Pablo; Sinning O., Mariana; Millán A., María; Miranda C., Marcelo; Robles G., Ignacio; Astudillo A., Priscilla; Peña, Sofia.
Rev. chil. neuro-psiquiatr ; 44(1): 9-14, mar. 2006. ilus, tab
Artículo en Español | LILACS | ID: lil-476925

Documentos relacionados

  1. Ecopipam as a pharmacologic treatment of stuttering.
  2. Exploratory cross-over, trial of augmented RLS with the dopamine receptor 1/5 antagonist ecopipam D1/D5 antagonist ecopipam for augmented RLS.
  3. Pyridoxine Synergistically Potentiates Mast Cell-Stabilizing Property of Ascorbic Acid.
  4. Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
  5. New and emerging treatments for symptomatic tardive dyskinesia.
  6. Droperidol for the treatment of acute migraine headaches.
  7. Amisulpride: A New Drug for Management of Postoperative Nausea and Vomiting.
  8. The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy?
  9. Dopamine Agonist Cotreatment Alters Neuroplasticity and Pharmacology of Levodopa-Induced Dyskinesia.
  10. Intravenous Chlorpromazine as Potentially Useful Treatment for Chronic Headache Disorders.